Cardiol Therapeutics Inc. CRDL
At closeNov 10, 2026, 4:00 AM EST
Pre-market · Nov 10, 4:00 AM ET
- YTD
- +7.97%
- 1 year
- +0.98%
- Market cap
- 125.16M
- EPS (ttm)
- -0.25
- Shares out
- 81.60M
- Forward P/E
- -4.03
- YTD return
- +7.97%
- 1-year return
- +0.98%
- Volume
- 401.37K
- Avg volume
- 1.36M
- Open
- 0.9909
- Previous close
- 0.995
- Day's range
- 0.97525 – 1.06
- 52-week range
- 0.88 – 2.34
- Beta
- 0.70
- Analysts
- Buy
- Price target
- 8.70 (+744.6%)
- Earnings date
- Aug 12, 2024
5D -0.04 (-3.81%)
Key statistics
- Enterprise value
- 103.33M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.63M
- Total cash
- 24.02M
- Total debt
- 164.27K
- Return on equity
- -108.43%
- Short % of float
- 1.06%
- 50-day average
- 1.70
- 200-day average
- 1.95
Analyst view
Consensus: buy
- Target (low)
- 7.80
- Target (mean)
- 8.70
- Target (high)
- 9.78
- Strong buy4
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.10 | -0.13 | -0.03 | -30.00% |
| Aug 12, 2024 | Jun 1, 2024 | -0.10 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -0.10 | -0.07 | +0.03 | +30.00% |
| May 14, 2024 | Mar 1, 2024 | -0.06 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.06 | -0.10 | -0.04 | -66.67% |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.09 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 26, 2024 | Roth MKM | init | — | Buy |
| Jun 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- cardiolrx.com
News
Your note
Sign in to keep a note on CRDL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tejara Capital Ltd | 2.17% | 1,771,270 | 2.21M | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 1.43% | 1,170,869 | 1.46M | Sep 29, 2024 |
| MMCAP International, Inc. SPC | 0.97% | 795,625 | 994.53K | Sep 29, 2024 |
| Lion Street Advisors, LLC | 0.33% | 273,281 | 341.60K | Sep 29, 2024 |
| Foundations Investment Advisors, Llc | 0.20% | 161,950 | 202.44K | Sep 29, 2024 |
| MGO One Seven, LLC | 0.12% | 100,000 | 125.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Pure Cannabis ETF | 1.28% | 1,047,249 | 1.31M | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 52,435 | 65.54K | Oct 30, 2024 |